HPV-Related Squamous Cell Carcinoma
Conditions
Keywords
Vaccine, Gene Therapy, TheraT®, E7E6, HPV 16 E7E6, HNSCC, HPV 16+ head and neck squamous cell cancer, Oropharyngeal cancer, HPV16, HPV 16, Head and neck cancer, Carcinoma, Carcinoma, squamous cell, Squamous cell carcinoma of head and neck, Neoplasms, squamous cell, Head and neck neoplasms, Pembrolizumab
Brief summary
This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 & HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts: Phase I Dose Escalation and Phase II Dose Expansion.
Detailed description
HB-201 and HB-202 are study drugs which are designed to train the body to recognize and fight substances found in HPV 16+ cancer. This trial studies the safety and anti-cancer effect of HB-201 and HB-202 in people. The trial is enrolling patients with metastatic/recurrent head and neck cancer who have not yet received treatment in this setting (1L, first line) and who are eligible to receive pembrolizumab as part of their standard of care. This trial is also enrolling patients with metastatic/recurrent head and neck who have received prior treatment in this setting (2L+, second and later line) who are eligible to receive pembrolizumab as part of their standard of care. Patients will receive the study drugs in addition to their pembrolizumab standard of care regimen.
Interventions
DRUGHB-201 intravenous administration.
Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
DRUGHB-202 intravenous administration alternating with HB-201 intravenous administration.
Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
DRUGHB-201 intravenous administration + standard of care regimen including pembrolizumab.
Dose Expansion
DRUGHB-202 / HB-201 alternating intravenous administration + pembrolizumab.
Dose Expansion
DRUGHB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab.
Dose Expansion
DRUGHB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Dose escalation; 10 patients
Sponsors
Hookipa Biotech GmbH
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All Patients: * Documentation of confirmed HPV 16+ cancer via genotype testing. * ≥ 1 measurable lesion by imaging for tumor response following RECIST * ECOG performance status of 0 to 1. * Prior curative radiation therapy and prior focal palliative completed per protocol-specified wash-out windows. * Screening laboratory values must meet protocol-specified criteria. * Able to provide tumor tissue following last treatment, unless otherwise agreed. Treatment Group E or Group F: * Documentation of confirmed head and neck squamous cell carcinoma. * Eligible to receive pembrolizumab, per standard of care and product label. * Group E: this group includes first line / 1L patients who have not yet received treatment in the metastatic/recurrent setting. * Group F: Tumor progression or recurrence on standard of care therapy, including ≥1 systemic therapy. Imaging Sub-Study (for specific participants at Memorial Sloan Kettering Cancer Center only): * Meeting requirements of inclusion criteria for Treatment Group 1 or Group 3. * At least 1 non-irradiated measurable lesion documented through imaging.
Exclusion criteria
All patients: * Metastatic central nervous system disease, and/or carcinomatous meningitis. * Any serious or uncontrolled medical disorder that, in the opinion of the Investigator, may increase the risk associated with study participation / treatment administration. * Concurrent malignancy that is clinically significant or requires active intervention, unless protocol-defined criteria are met. * Active, known or suspected, autoimmune or inflammatory disorders requiring immunosuppressive therapy. * Has a life expectancy of less than 3 months. * Any toxicities attributed to systemic prior anticancer therapy o that have not resolved to Grade 1 or baseline prior to the first administration of study drug, unless protocol-defined criteria is met. * Not meeting the protocol-specified washout periods for prohibited medications. * Prior anaphylactic reaction to or known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s). * Positive hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody, indicating acute or chronic infection. * Known history of acquired immunodeficiency syndrome. For patients in Groups E or F and certain backfill cohorts: * History of severe hypersensitivity reaction to or other contraindication to receiving pembrolizumab. * History of/Presently having non-infectious pneumonitis requiring treatment. * Was discontinued due to a Grade 3 or higher immune-related AE (irAE) after receiving prior therapy with check point inhibitors. Imaging Sub-Study (for specific participants at Memorial Sloan Kettering Cancer Center only): * Having splenic disorders or prior splenectomy, and can compromise protocol objectives per Investigator and/or Sponsor. * Meeting requirements of
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase I Dose Escalation: Determine Phase II dose based on incidence of dose-limiting toxicities. | From dosing until 21-28 days after first dose | Determine the recommended Phase II dose in terms of safety and tolerability for intravenously administered HB-201, and intravenously administered HB-202 by assessing drug limiting toxicities. |
| Phase II Dose Expansion: Number of participants with preliminary antitumor activity based on objective response rate. | Until progression, (estimated up to 30-months) | Assess the preliminary antitumor activity of dosage regimens of HB-201 and HB-202 using Response Evaluation Criteria in Solid Tumors (RECIST) to determine objective response rate (ORR). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase I Dose Escalation: Number of participants with adverse events (type, frequency, severity). | From informed consent through 30 days after last dose. | Assess the safety and tolerability of dosage regimens of HB-201 and HB-202 by monitoring the type, frequency, and severity of AEs and SAEs by monitoring the type, frequency, and severity of AEs and SAEs. |
| Phase I Dose Escalation: Number of participants with preliminary antitumor activity based on objective response rate and disease control rate. | Until progression, (estimated up to 30-months) | Assess the preliminary antitumor activity of dosage regimens of HB-201 and HB-202 using RECIST and iRECIST |
| Phase II Dose Expansion: Number of participants with confirmed duration of preliminary antitumor activity. | Up to 30-months (until progression) | Confirm duration of preliminary antitumor activity of dosage regimens of HB-201 and HB-202 alone of in combination with pembrolizumab, using RECIST and iRECIST |
| Phase II Dose Expansion: Number of participants with adverse events (type, frequency, severity). | From informed consent through 30 days after last dose | Assess the safety and tolerability of dosage regimens of HB-201 and HB-202 alone or in combination with pembrolizumab by monitoring the type, frequency, and severity of AEs and SAEs. |
Countries
Netherlands, Spain, United States
Outcome results
None listed